Vitamin K for the primary prevention of cardiovascular disease.

Study answer

What this study found

Vitamin K2 (MK-7) did not show meaningful effects on blood pressure or lipid levels over 12 weeks, and no clinical cardiovascular outcomes were reported. In the 180 µg/day arm, the mean difference versus placebo was -6.75 for systolic blood pressure, 0.0 for diastolic blood pressure, 0.20 for total cholesterol, 0.0 for LDL-C, 0.0 for HDL-C, and 0.1 for triglycerides. In the 360 µg/day arm, the corresponding mean differences were 1.74, 2.32, -0.10, 0.20, 0.0, and 0.1. The evidence base is extremely limited, so no firm conclusion can be drawn about vitamin K for primary prevention of…

Study & population

Systematic review of randomized trial evidence for primary prevention of cardiovascular disease, with one included study in apparently healthy adults from the Netherlands.

Intervention

Vitamin K2 as menaquinone-7 (MK-7) was given orally for 12 weeks in two active regimens: 180 µg/day as one MK-7 capsule plus one placebo capsule daily, or 360 µg/day as two MK-7 capsules daily.

Key limitation

Evidence came from only one small randomized trial with short 12-week follow-up, so clinical cardiovascular prevention cannot be assessed.

View full study detailsView sourceOpen PDF

Original abstract